Strategies for clinical dose optimization of T cell-engaging therapies in oncology

por Ball, Kathryn, Dovedi, Simon J, Vajjah, Pavan, Phipps, Alex
Publicado 2023

Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis

por Williams, Cayman, Kennedy, Alan, Robinson, Maximillian A., Lloyd, Christopher, Dovedi, Simon J., Sansom, David M.
Publicado 2022

Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 exp...

por Oguejiofor, Kenneth, Galletta-Williams, Henry, Dovedi, Simon J., Roberts, Darren L., Stern, Peter L., West, Catharine M.L.
Publicado 2017

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80

por Kennedy, Alan, Robinson, Maximillian A, Hinze, Claudia, Waters, Erin, Williams, Cayman, Halliday, Neil, Dovedi, Simon, Sansom, David M
Publicado 2023

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model

por Kosinsky, Yuri, Dovedi, Simon J., Peskov, Kirill, Voronova, Veronika, Chu, Lulu, Tomkinson, Helen, Al-Huniti, Nidal, Stanski, Donald R., Helmlinger, Gabriel
Publicado 2018

Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized mice

por Matas-Céspedes, Alba, Lapointe, Jean-Martin, Elder, Matthew J., Browne, Gareth J., Dovedi, Simon J., de Haan, Lolke, Maguire, Shaun, Stebbings, Richard
Publicado 2023

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments

por Sitnikova, Suzanne I., Walker, Jennifer A., Prickett, Laura B., Morrow, Michelle, Valge-Archer, Viia E., Robinson, Matthew J., Wilkinson, Robert W., Dovedi, Simon J.
Publicado 2023

A cell-engineered system to assess tumor cell sensitivity to CD8(+) T cell-mediated cytotoxicity

por Nelson, Nadine, Lopez-Pelaez, Marta, Palazon, Asis, Poon, Edmund, De La Roche, Maike, Barry, Simon, Valge-Archer, Viia, Wilkinson, Robert W., Dovedi, Simon J., Smith, Paul D.
Publicado 2019

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

por Lopez-Pelaez, Marta, Young, Lucy, Vazquez-Chantada, Mercedes, Nelson, Nadine, Durant, Steve, Wilkinson, Robert W., Poon, Edmund, Gaspar, Miguel, Valge-Archer, Viia, Smith, Paul, Dovedi, Simon J.
Publicado 2022

Cyton2: A Model of Immune Cell Population Dynamics That Includes Familial Instructional Inheritance

por Cheon, HoChan, Kan, Andrey, Prevedello, Giulio, Oostindie, Simone C., Dovedi, Simon J., Hawkins, Edwin D., Marchingo, Julia M., Heinzel, Susanne, Duffy, Ken R., Hodgkin, Philip D.
Publicado 2021

A LAT-Based Signaling Complex in the Immunological Synapse as Determined with Live Cell Imaging Is Less Stable in T Cells with Regulatory Capability

por Li, Yikui, Tunbridge, Helen M., Britton, Graham J., Hill, Elaine V., Sinai, Parisa, Cirillo, Silvia, Thompson, Clare, Fallah-Arani, Farnaz, Dovedi, Simon J., Wraith, David C., Wülfing, Christoph
Publicado 2021

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

por Dovedi, Simon, Adlard, Amy, Lipowska-Bhalla, Grazyna, McKenna, Conor, Jones, Sherrie, Cheadle, Eleanor, Stratford, Ian, Poon, Edmund, Morrow, Michelle, Stewart, Ross, Jones, Hazel, Wilkinson, Robert W, Honeychurch, Jamie, Illidge, Tim
Publicado 2014

A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

por Adlard, Amy L, Dovedi, Simon J, Telfer, Brian A, Koga-Yamakawa, Erina, Pollard, Charlotte, Honeychurch, Jamie, Illidge, Timothy M, Murata, Masashi, Robinson, David T, Jewsbury, Philip J, Wilkinson, Robert W, Stratford, Ian J
Publicado 2014

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

por Nakamura, Kyoko, Karmokar, Ankur, Farrington, Paul M., James, Neil H., Ramos-Montoya, Antonio, Bickerton, Susan J., Hughes, Gareth D., Illidge, Timothy M., Cadogan, Elaine B., Davies, Barry R., Dovedi, Simon J., Valge-Archer, Viia
Publicado 2021

Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma

por Egan, Donagh, Kreileder, Martina, Nabhan, Myriam, Iglesias-Martinez, Luis F., Dovedi, Simon J., Valge-Archer, Viia, Grover, Amit, Wilkinson, Robert W., Slidel, Timothy, Bendtsen, Claus, Barrett, Ian P., Brennan, Donal J., Kolch, Walter, Zhernovkov, Vadim
Publicado 2023

Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

por Sitnikova, Suzanne Isabelle, Munnings-Tomes, Sophie, Galvani, Elena, Kentner, Stacy, Mulgrew, Kathy, Rands, Chris, España Agustí, Judit, Zhang, Tianhui, Ilieva, Kristina M, Rosignoli, Guglielmo, Ghadially, Hormas, Robinson, Matthew J, Slidel, Tim, Wilkinson, Robert W, Dovedi, Simon J
Publicado 2021

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

por Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Publicado 2017

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination...

por Dovedi, Simon J., Adlard, Amy L., Ota, Yosuke, Murata, Masashi, Sugaru, Eiji, Koga-Yamakawa, Erina, Eguchi, Ken, Hirose, Yuko, Yamamoto, Setsuko, Umehara, Hiroki, Honeychurch, Jamie, Cheadle, Eleanor J., Hughes, Gareth, Jewsbury, Philip J., Wilkinson, Robert W., Stratford, Ian J., Illidge, Timothy M.
Publicado 2016

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

por Harper, James, Burke, Shannon, Travers, Jon, Rath, Nicola, Leinster, Andrew, Navarro, Christel, Franks, Ruth, Leyland, Rebecca, Mulgrew, Kathy, McGlinchey, Kelly, Brown, Lee, Dovedi, Simon J., Koopmann, Jens-Oliver, Durham, Nicholas M., Cheng, Xing, Jin, Hong, Eyles, Jim, Wilkinson, Robert W., Carroll, Danielle
Publicado 2021

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

por Mullins, Stefanie R., Vasilakos, John P., Deschler, Katharina, Grigsby, Iwen, Gillis, Pete, John, Julius, Elder, Matthew J., Swales, John, Timosenko, Elina, Cooper, Zachary, Dovedi, Simon J., Leishman, Andrew J., Luheshi, Nadia, Elvecrog, James, Tilahun, Ashenafi, Goodwin, Richard, Herbst, Ronald, Tomai, Mark A., Wilkinson, Robert W.
Publicado 2019